A cancer patient in Lebanon receives chemotherapy in 2025. The treatment fails. Investigators later confirm the vials contained no active ingredient — they were counterfeits that had entered the official supply chain and made it all the way to a hospital ward. The case made international headlines, but it was not an isolated incident. It was a visible example of a problem that plays out, largely unseen, thousands of times a year across more than 140 countries.

For pharmaceutical brand owners and supply chain managers, counterfeit medicines are not a distant threat to be managed by regulators alone. They are a direct business risk — one that can destroy patient trust built over decades, trigger regulatory penalties, and remove revenue that should belong to your legitimate product. And they are getting harder to detect. Modern counterfeits replicate packaging, labelling, and batch codes with a precision that makes visual inspection essentially useless.

This article explains the full scope of the counterfeit pharmaceutical problem, why conventional defences are no longer enough, how the regulatory environment is shifting, and what authentication and track-and-trace technologies can realistically do to close the gaps in your supply chain. The goal is to give you a clear picture of the risk and a practical framework for addressing it.

The Scale of the Problem

The numbers are striking, but they also understate the real exposure. The WHO estimates that close to $83 billion worth of counterfeit drugs are sold annually, with one in 10 medical products circulating in developing countries being substandard or falsified. The Pharmaceutical Security Institute (PSI), which tracks confirmed incidents globally, recorded 6,987 reported counterfeit drug incidents across 142 countries in 2023 — a 4% increase from the prior year — and that figure climbed further in 2025, when the PSI logged 7,152 confirmed cases of pharmaceutical counterfeiting, illegal diversion, and theft, an 18% increase in distinct medicines affected compared with 2024. Criminal groups are not just targeting common medications: PSI data shows that in 2025 alone, 756 distinct medicines across 16 therapeutic areas were counterfeited, including life-saving oncology and immunotherapy treatments.

The Asia-Pacific region sits at the heart of this challenge. INTERPOL reported that counterfeit medicine seizures in the Asia Pacific region increased by 40% between 2021 and 2023, with online pharmacies serving as a major distribution channel. The region’s rapidly expanding pharmaceutical manufacturing base, combined with complex cross-border distribution networks and uneven regulatory enforcement across markets, creates the exact conditions that counterfeit operators exploit. For any brand selling into or within APAC, that exposure is not theoretical.

Why Pharmaceuticals Are Such an Attractive Target

Counterfeit operators choose their targets rationally. Pharmaceuticals offer high margins, consistent demand, and a consumer who, by necessity, trusts the product they receive. Unlike a fake handbag, a fake medicine requires no convincing lifestyle pitch — the patient simply needs it. The rise of digital pharmacies and online marketplaces has dramatically lowered the barrier to distribution: up to 50% of medicines purchased from unregulated online pharmacies have been found to be fake. These channels reach consumers who are cost-conscious, in remote areas, or navigating drug shortages — exactly the populations least likely to have access to a trusted local dispensary.

There is also a production economics argument. Producing a tablet with no active ingredient, or with only a fraction of the required dose, is cheap. The counterfeit operator captures near-full retail price while bearing almost no manufacturing cost. The profit incentive is enormous, which explains why the anti-counterfeit pharmaceutical packaging market — the industry’s response — is expected to grow from approximately $6.1 billion in 2025 to $12.5 billion by 2035, as brands and manufacturers invest in protection that counterfeiters cannot easily replicate.

The Real-World Consequences: Patient Safety, Brand Damage, and Legal Exposure

The most immediate consequence is patient harm. Falsified medicines risk three key areas: quality, safety, and efficacy. A product without the correct active ingredient simply does not work, which in the context of cancer treatment, antimicrobials, or cardiovascular drugs, can be fatal. Counterfeit antimicrobials carry a second-order risk: they contribute directly to drug resistance, a problem the WHO describes as one of the greatest global health threats of this century. When patients receive an ineffective version of a legitimate medicine and the treatment fails, the clinical and reputational damage attaches to the brand name on the packaging, not to the counterfeiter who produced it.

For the pharmaceutical company, the consequences extend well beyond reputational harm. Regulatory agencies in more than 70 countries now mandate some form of pharmaceutical serialisation or track-and-trace compliance. A brand found to be operating in a market without adequate authentication controls — even if the counterfeits were introduced by a third party — faces the prospect of fines, product recalls, and suspension of distribution licences. Legal exposure compounds the commercial damage. In markets with active enforcement regimes, non-compliant manufacturers can face being barred from product launches entirely, cutting off revenue from new treatments before they reach patients.

How Counterfeits Enter the Supply Chain

The counterfeit medicine problem is often framed as a manufacturing challenge — illegal operators produce fake drugs, regulators seize them, and brands try to protect their packaging. But the structure of modern pharmaceutical commerce makes that definition increasingly incomplete. Medicines can be manufactured in one country, packaged in another, and distributed across multiple borders before they reach a patient. At each handoff point, the chain of custody can be broken, and a counterfeit or diverted product can slip in.

The specific entry points vary, but several patterns are well-documented. Grey market diversion occurs when legitimate product manufactured for one geography is diverted and resold in another, often at inflated prices, bypassing the authorised distribution network entirely. Parallel imports exploit price differentials between markets, with the product’s provenance becoming harder to verify with each additional intermediary. Overrun fraud involves authorised manufacturers producing volumes beyond their licensed quota and selling the surplus through unofficial channels. And in markets with weak regulatory oversight, counterfeit product can enter hospital and pharmacy supply directly, as has been documented repeatedly across Southeast Asia and the Middle East. Supply chain vulnerabilities — including inadequate cold chain storage, weak logistics networks, and limited traceability — make it easier for bad product to reach the end user undetected.

The Evolving Regulatory Landscape

Regulation is moving faster than many pharmaceutical brands realise. The EU’s Falsified Medicines Directive (FMD), which came into full effect in 2019, mandates serialisation of prescription medicines, requiring manufacturers to include a unique identifier — composed of a product code, a randomised serial number, a batch number, and an expiry date — plus an anti-tampering device on every pack. The practical impact of this system was demonstrated clearly in 2023, when falsified semaglutide (Ozempic) was identified in Germany: scanning revealed inactive serial numbers, which triggered an alert and allowed investigators to trace the product back through Austrian and German wholesalers via the EU-wide electronic system.

The United States’ Drug Supply Chain Security Act (DSCSA) established equivalent requirements in the US market, and similar mandates are now in place or being introduced across Saudi Arabia, South Korea, Brazil, and multiple MENA markets. Globally, between 70 and 80% of countries have mandated some form of pharmaceutical serialisation legislation. Governments across Asia-Pacific are enforcing product-level tracking regulations for pharmaceuticals and healthcare products with increasing rigour, and the APAC track-and-trace solutions market reflects that — it was valued at USD 1.18 billion in 2025 and is projected to reach USD 8.55 billion by 2035, growing at a CAGR of approximately 21.9%. For pharmaceutical brands operating across multiple APAC markets, compliance is no longer a future consideration; it is a present operational requirement with real penalties for non-compliance.

Authentication Technologies That Actually Work

For decades, the standard anti-counterfeit toolkit for pharmaceutical packaging consisted of holograms, embossed seals, and colour-shifting inks. These remain useful as visible deterrents, but they are no longer sufficient on their own. Counterfeit operators now replicate physical security features with a quality that defeats visual inspection by untrained eyes. The technologies that actually move the needle combine physical authentication with a digital layer that is far harder to clone.

Serialised Security QR Codes

A serialised security QR code is not the same as a standard QR code. Each code is unique to an individual unit — not just a batch — and is generated using an encrypted algorithm. When a consumer, pharmacist, or inspector scans the code, the system checks it against a central database in real time. If the code has never been scanned, the product is likely authentic. If it has been scanned multiple times in different locations, that pattern is a strong signal of counterfeiting or diversion. Some implementations go further, building overt and covert layers into the code itself: the visible portion provides consumer-facing information, while a hidden cryptographic layer can only be read by authorised verification systems. Serialised QR codes can often be integrated into existing print processes with minimal modification, which makes them one of the more accessible entry points for pharmaceutical brands beginning to build authentication infrastructure.

NFC Tags

Near field communication (NFC) tags embedded in pharmaceutical packaging offer a higher level of security than printed codes alone. When a consumer or healthcare professional taps the packaging with an NFC-enabled smartphone — no app required — the tag communicates with a verification server and returns an authenticity result in seconds. Advanced NFC chips use AES-128 encryption and generate a unique, encrypted URL with every single tap, which means that even if a counterfeiter photographs or copies the tag’s surface, replaying the same interaction will not produce a valid authentication result. Some NFC implementations also include tamper detection: once the packaging seal is broken, the tag registers the event, making it immediately visible to anyone who scans it subsequently. For premium pharmaceutical products, biologics, and high-value treatments where the cost of counterfeiting to the patient is highest, NFC provides a level of authentication that conventional techniques cannot match.

Batch Verification and Serialised Packaging

Beyond individual-unit authentication, batch-level verification allows distributors, wholesalers, and pharmacy chains to confirm that a consignment of product matches what was dispatched by the manufacturer. Every package in a shipment carries a serialised identifier, and the aggregate of those identifiers — the batch manifest — travels with the consignment. If product is removed, substituted, or added during transit, the manifest discrepancy flags the anomaly. This approach, combined with anti-tampering devices on the outer packaging, closes one of the most common routes for counterfeit product to enter a legitimate supply chain: the substitution of real product with fake during distribution.

Track-and-Trace: Visibility Across the Entire Chain

Authentication at the product level tells you whether an individual unit is genuine. Track-and-trace tells you where every unit of your product is, has been, and should be — and it alerts you when something does not add up. For manufacturers tracking medicines across complex cross-border distribution networks, this distinction matters enormously. A product may carry a genuine authentication label and still represent a diversion problem if it is appearing in a market it was never licensed for, at a price point that undercuts your authorised channel, or in volumes that exceed what was legitimately shipped.

Modern smart track-and-trace platforms generate real-time supply chain visibility by aggregating scan events at each custody transfer point — manufacturer, freight forwarder, distributor, wholesaler, pharmacy. That data reveals diversion patterns, identifies grey market activity, and surfaces supply chain irregularities before they scale into serious brand or compliance problems. For regulatory reporting, it also provides the auditable chain of custody that serialisation mandates require. The industry’s goal is shifting from identifying fake medicines after the fact to proving provenance — creating a continuous, verifiable record from manufacturer to patient. Track-and-trace is the operational infrastructure that makes that possible.

Nabcore’s Smart Tracking solution is designed with exactly this challenge in mind — giving pharmaceutical brands real-time visibility into where product is moving, flagging anomalies in distribution patterns, and supporting the evidence trail needed for both regulatory compliance and enforcement action against counterfeiters.

Empowering Consumers to Verify at the Point of Sale

One dimension of pharmaceutical authentication that is frequently underestimated is the consumer. Patients who have been harmed by a counterfeit medicine, or who have reason to doubt the product in their hands, need a simple, fast, and reliable way to verify authenticity without specialist knowledge or equipment. Some companies incorporate QR codes and NFC-enabled labels into their packaging specifically for this reason: by scanning the code, consumers can access product information including manufacturing details, expiry date, and batch number, and receive a clear verification result. This mechanism does more than protect patient safety in the moment — it actively builds consumer trust in the brand and creates a direct, documented connection between the consumer and the manufacturer.

Post-purchase consumer engagement through smart packaging also generates data that is valuable in its own right. Scan data reveals where and when products are being verified, at what frequency, and in which geographies. Anomalous scan patterns — high verification volumes in a market where you have limited authorised distribution, for example — are early warning signals of grey market activity or counterfeiting that would otherwise be invisible until a regulatory complaint or adverse event report surfaced the problem. This is a dimension of consumer engagement that pharmaceutical brands are increasingly building into their protection strategies: the consumer becomes a distributed sensor network for supply chain integrity.

Building a Protection Strategy That Fits Your Risk Profile

The right authentication and track-and-trace approach is not the same for every pharmaceutical brand. The combination of technologies that makes sense depends on several variables: the value and vulnerability of the product, the markets in which it is sold, the complexity of the distribution network, the regulatory requirements that apply in each market, and the production infrastructure already in place. A high-value oncology treatment distributed across 12 countries through multiple wholesale layers has a very different risk profile from an over-the-counter product sold through a single retail chain in one market.

A few questions are worth working through before selecting a solution approach:

• Where in your supply chain is the greatest vulnerability? For some brands, the risk is at the manufacturing overrun stage; for others, it is in distribution or at the retail point of sale. The authentication layer needs to address the actual point of failure, not just the most visible one.
• What do your target markets require in terms of regulatory compliance? Pharmaceutical serialisation requirements, market-specific labelling regulations, and emerging digital product passport frameworks may constrain or define the technical specifications your solution must meet.
• What data do you need, and what will you do with it? Authentication programmes generate scan data. If you are not set up to analyse it, you will miss the early warning signals it contains. A solution that produces data without an analytical layer attached to it is only doing half the job.
• How will consumers interact with the verification mechanism? A QR code that requires a proprietary app download will be used by almost no one. The most effective consumer-facing verification tools work with a standard smartphone camera and return a clear, immediate result.

Nabcore’s product authentication solutions and anti-copy security QR codes are built around this kind of risk-profile thinking. Rather than deploying a fixed technology stack, the approach starts with a consultation to understand where a brand’s specific vulnerabilities lie, then designs an interlocking combination of authentication, tracking, and engagement capabilities tailored to that profile. With more than 14 years of experience protecting products across 11 countries in the Asia-Pacific region — and over 300 million products protected to date — the team brings regional regulatory knowledge and implementation depth that a generic platform approach cannot replicate. You can explore the full range of available solutions at the Nabcore Solutions Hub, or see how the approach translates to the pharmaceutical and healthcare sector through the case studies library.

The Stakes Are High Enough to Act Now

Counterfeit pharmaceuticals are not a background risk that brands can afford to manage reactively. The combination of rising incident volumes, an increasingly aggressive regulatory environment across Asia-Pacific and beyond, and the direct patient harm that fake medicines cause means that the cost of inaction — measured in brand damage, regulatory penalties, lost revenue, and human consequences — now exceeds the cost of building a serious protection programme. The good news is that the technologies to address this problem are mature, deployable, and increasingly affordable. Serialised security codes, NFC-enabled packaging, and smart track-and-trace systems can be designed to work within existing manufacturing and logistics infrastructure, and they generate intelligence that improves supply chain operations well beyond their anti-counterfeiting function.

The question for most pharmaceutical brand owners is not whether to act, but how to sequence the investment in a way that addresses the highest-risk exposures first. That starts with an honest assessment of where your supply chain is most vulnerable — and building outward from there.